Department of Pulmonary Medicine. Menemen State Hospital, Izmir, Turkey(1).
Department of Pulmonary Medicine, Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey(2).
Respir Med. 2021 Mar;178:106310. doi: 10.1016/j.rmed.2021.106310. Epub 2021 Jan 22.
Since GOLD 2017 separates spirometry results from 'ABCD' groups, there have been some changes to the stages of COPD patients. Our aim was to investigate the shifts in COPD groups after GOLD 2017.
COPD patients from outpatient clinics of 3 hospitals in Turkey were stratified into old and new ABCD groups according to exacerbation history, mMRC evaluation and spirometry results for both GOLD 2011 and 2017 assessments. Treatment protocols were also evaluated if they were suitable for both classifications.
There were 578 patients (334 men, 244 women) with a mean age of 65.21±10.42. The distribution of patients from group A to D was 28%, 15%, 15%, 42% (GOLD 2011) and 36%, 22%, 7% and 35% (GOLD 2017) respectively. There were shifts from group C to A (53.4%) and D to B (18.4%). The treatment suitability was 66.3% in GOLD 2011 and 60.9% in GOLD 2017. The most common inappropriate treatment protocol was triple therapy. Presence of exacerbations in last year, mMRC score, FEV1 level (p < 0.01 for three parameters) and proportion of males (p = 0.029) were statistically significantly higher in groups C and D of GOLD 2017 compared with new patients in group A and B of GOLD 2017 (shifted from GOLD 2011's C-D groups).
There were shifts from group C to A and D to B with GOLD 2017, which means some high-risk COPD patients were reclassified into low-risk groups. Despite guideline updates, there are still many COPD patients with overtreatment. To our knowledge, this is the first study examining transitions between COPD groups after GOLD 2017 in Turkey.
自 2017 年 GOLD 版指南将肺功能结果从“ABCD”组中分离出来后,COPD 患者的分期发生了一些变化。我们的目的是探讨 GOLD 2017 版指南实施后 COPD 患者分组的变化情况。
根据加重史、mMRC 评估和 2011 年和 2017 年两次 GOLD 评估的肺功能结果,将土耳其 3 家医院门诊的 COPD 患者分为旧的和新的 ABCD 组。还评估了治疗方案是否适合两种分类。
共有 578 例患者(334 例男性,244 例女性),平均年龄为 65.21±10.42 岁。从组 A 到 D 的患者分布分别为 28%、15%、15%和 42%(GOLD 2011 年)和 36%、22%、7%和 35%(GOLD 2017 年)。从组 C 到 A(53.4%)和从组 D 到 B(18.4%)转移。GOLD 2011 年治疗适宜率为 66.3%,GOLD 2017 年为 60.9%。最常见的不适当治疗方案是三联疗法。在过去一年中发生加重、mMRC 评分、FEV1 水平(三个参数均为 p<0.01)和男性比例(p=0.029)在 GOLD 2017 年的 C 组和 D 组(从 GOLD 2011 年的 C-D 组转移而来)与 GOLD 2017 年新的 A 组和 B 组患者相比均有统计学显著升高。
GOLD 2017 版指南实施后,C 组转移到 A 组,D 组转移到 B 组,这意味着一些高危 COPD 患者被重新分类到低危组。尽管指南更新,但仍有许多 COPD 患者存在过度治疗。据我们所知,这是土耳其首个研究 GOLD 2017 版指南实施后 COPD 患者分组变化的研究。